Metoprolol: an old drug with unique cardioprotective properties

October 09, 2020

A drug costing less than 2 euros per dose could reduce the long term consequences of a heart attack, benefitting millions of patients. Metoprolol, a member of the beta-blocker class of drugs that has been in use for more than 40 years, has been found to have unique cardioprotective properties.

This is the conclusion of a study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Fundación Jiménez Díaz University Hospital, and the Cardiovascular Disease Research Network (CIBERCV). The study, performed in sophisticated experimental mouse models, shows that the cardioprotective effect of metoprolol during a heart attack is not shared by other beta-blockers commonly administered by intravenous injection, such as atenolol and propranolol.

The European Heart Journal study [1] was led by Dr Borja Ibáñez, head of Clinical Research at the CNIC, a cardiologist at Fundación Jiménez Díaz University Hospital, and a CIBERCV group leader. The research "demonstrates that metoprolol has unique cardioprotective properties and heralds a paradigm change in cardiology and the treatment of acute myocardial infarction," said Dr Ibañez.

In 2013, the METOCARD-CNIC clinical trial, led and coordinated by the CNIC, showed that administration of metoprolol very early during an infarction limits damage to the heart and reduces long term consequences.

Four years later, in 2017, the same research team showed how and why this cheap and simple therapeutic strategy is so efficient. In a study published in Nature Communications, the researchers showed that the cardioprotective potential of metoprolol lies in its ability to block the action neutrophils--inflammatory cells activated during infection to eliminate pathogens--preventing them from entering the infarcted heart tissue.

Now, in 2020, the team has shown that metoprolol's cardioprotective properties are not shared by other beta-blockers and are thus not a class effect.

"The study presents important results that update and refine cardiovascular pharmacotherapy and underline how important it is not to assume that drugs in the same class will have identical activities and clinical indications," said pharmacist Agustín Clemente, a doctoral candidate at the CNIC and first author on the article.

Acute myocardial infarction is one of the main manifestations of cardiovascular disease and is the leading cause of death in the world. In Spain, more than 70 000 people have a heart attack every year. Current treatment guidelines recommend early administration of beta-blockers to patients with symptoms of an infarction but do not distinguish between the different drugs in this class. This is why the new results are so clinically significant.

Neutrophils, as well as protecting against infection, can become hyperactivated in other situations, such as during a myocardial infarction, when they can cause significant additional injury to the heart. Metoprolol is able to limit this hyperactivation, thereby preventing inflammatory damage associated with infarction.

The study also assessed the effects of different beta-blockers in other models of inflammatory disease, like lung damage and peritonitis. In all models examined, metoprolol was the only beta-blocker able to limit the organ damage inflicted by hyperactivated neutrophils. These findings could have an impact on the treatment of diseases in which injury is linked to neutrophil hyperactivation, including sepsis and possibly even COVID-19.

Building on the knowledge generated about metoprolol's cardioprotective effect, the research team used 3D intravital microscopy to investigate the effect of the drug on neutrophils. "This advanced imaging technology allowed us to study changes in cell movement and shape induced by metoprolol and to exclude a direct effect on these cells of other intravenous beta-blockers like atenolol or propranolol," explained Agustín Clemente.

Working with the CNIC Bioinformatics Unit, the research team conducted computational studies to assess the impact of different beta-blockers on type 1 beta adrenergic receptors, the molecular target of these drugs. "Unexpectedly, we found that despite their related chemical structures each drug interacts with beta-1 adrenergic receptors in a different way. This translates into a distinct structural change in the receptor for each drug, which in the case of metoprolol induces a specific molecular cascade and a concrete and unique cellular effect," commented co-principal investigator Dr Eduardo Oliver, a CNIC and CIBERCV pharmacologist and beneficiary of the Comunidad de Madrid talent program.

"Unlike other beta-blockers, metoprolol triggers a change in the intracellular structure of the beta-1 adrenergic receptor, opening it up so that it can interact with other nearby proteins that mediate the unique effect of metoprolol on neutrophil activity," added Dr Oliver.

Until now, beta-blockers were thought to act exclusively by impeding interaction between epinephrine and beta-1 adrenergic receptors. But the new results demonstrate that the binding of metoprolol not only blocks the action of epinephrine, but also activates other intracellular pathways, a phenomenon called biased agonism.

The authors conclude that metoprolol should be the beta-blocker of choice in clinical practice. "If these results are confirmed in future clinical studies, this would herald a change in the clinical guidelines for this devastating disease, placing metoproplol, and not other beta-blockers, as the drug of choice for patients suffering a heart attack," said Dr Ibañez.

The low cost of metoprolol, at less than 2 euros for an acute dose, brings additional value to this discovery.
-end-
About the CNIC

The Centro Nacional de Investigaciones Cardiovasculares (CNIC), directed by Dr. Valentín Fuster, is dedicated to cardiovascular research and the translation of knowledge gained into real benefits for patients. The CNIC, recognized by the Spanish government as a Severo Ochoa center of excellence, is financed through a pioneering public-private partnership between the government (through the Carlos III Institute of Health) and the Pro-CNIC Foundation, which brings together 12 of the most important Spanish private companies.

Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.